GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BPH Global Ltd (ASX:BP8) » Definitions » COGS-to-Revenue

BPH Global (ASX:BP8) COGS-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is BPH Global COGS-to-Revenue?

BPH Global's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was A$0.00 Mil.

BPH Global's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. BPH Global's Gross Margin % for the six months ended in Dec. 2023 was N/A%.


BPH Global COGS-to-Revenue Historical Data

The historical data trend for BPH Global's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BPH Global COGS-to-Revenue Chart

BPH Global Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 0.91 0.82 0.84 -

BPH Global Semi-Annual Data
Dec07 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.85 - - -

BPH Global COGS-to-Revenue Calculation

BPH Global's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

BPH Global's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BPH Global  (ASX:BP8) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

BPH Global's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


BPH Global COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of BPH Global's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BPH Global (ASX:BP8) Business Description

Traded in Other Exchanges
N/A
Address
96 Elizabeth Street, Block Arcade, Office 324, Level 3, Melbourne, VIC, AUS, 3000
BPH Global Ltd, formerly Stemcell United Ltd is a marine and agricultural biotechnology industry. Its only operating segment is sourcing, producing, marketing, and selling traditional medicines. The company's geographical segment includes Australia; Singapore; Malaysia and Greater China. The company's product comprises Cannabis sativa; Dendrobium Officinale and Daemonorops Draco Blume.

BPH Global (ASX:BP8) Headlines

No Headlines